Abstract
The effect of agents commonly used for osteoporosis treatment in Japan—calcium, alfacalcidol (1α-hydroxyvitamin D3), elcatonin (eel calcitonin derivative), and an alfacalcidol-elcatonin combination—on lumbar spine bone mineral density (BMD) was assessed in 136 subjects aged 51–83 years with various degrees of osteopenia or osteoporosis, divided into five groups approximately matched for age and BMD over a period of 3 years. Lumbar spine BMD decreased by about 3.5% without treatment but was maintained at approximately baseline level on elcatonin. Oral administration of 900mg/day calcium as AAA Ca (active absorbable algae calcium) or 1μg/day alfacalcidol increased lumbar BMD by 4.5% or 3.7%, respectively, after 3 years. Combined use of alfacalcidol and elcatonin was most effective, increasing the BMD by 8.0% after 3 years. Extremely low calcium and vitamin D intake in Japan with consequent low calcitonin secretion may be responsible for the favorable effects. Alfacalcidol, an active form of vitamin D, and elcatonin acting through different mechanisms may act synergistically on bone to increase BMD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fujita T (1996) Clinical guidelines for the treatment of osteoporosis in Japan. Calcif Tissue Int 59 [suppl 1]:S34-S37
Fujita T, Fukase M, Shimada T, Yamamoto H (1992) Treatment of established osteoporosis with 1α(OH) vitamin D3 and low dose intermittent elcatonin (eel calcitonin derivative). J Bone Miner Metab 10:37–40
Fujita T (1996) Calcium bioavailability from heated oyster shell-seaweed calcium (active absorbable algae calcium) as assessed by urinary calcium excretion. J Bone Miner Metab 14:31–34
Fujita T, Ohue T, Fujii Y, Miyauchi A, Takagi Y (1996) Heated oyster shell-seaweed calcium (AAACa) on osteoporosis. Calcif Tissue Int 58:226–230
Nicholson GC, Mosely JM, Sexton PM, Mendelsohn FAO, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78:355–360
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fracture in the elderly women. N Engl J Med 327:1637–1642
Overgaard K, Hansen MA, Dirksen KL, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rate in established osteoporosis. A double-responsive study. Br Med J 305:556–561
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Misiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79
Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Miller PD, Licata AA, Chesnut CH (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis. Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557–567
Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tilloston S, Santora AC II (1995) Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144–152
Lindsay R, Tohme JF (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76:1–6
Author information
Authors and Affiliations
About this article
Cite this article
Fujita, T., Fujii, Y., Goto, B. et al. A three-year comparative trial in osteoporosis treatment: Effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15, 223–226 (1997). https://doi.org/10.1007/BF02491385
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02491385